# Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee

> **NCT00928837** · NA · COMPLETED · sponsor: **Primus Pharmaceuticals** · enrollment: 350 (actual)

## Conditions studied

- Osteoarthritis

## Interventions

- **DIETARY_SUPPLEMENT:** Flavocoxid 500 mg
- **DRUG:** Naproxen
- **OTHER:** Placebo
- **OTHER:** flavocoxid 250 mg

## Key facts

- **NCT ID:** NCT00928837
- **Lead sponsor:** Primus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-06
- **Final completion:** 2007-09
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2017-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00928837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00928837, "Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00928837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*